ClinicalTrials.gg
RecruitingNCT03959800Updated Aug 10, 2026

Molecular Basis of Pediatric Liver Cancer

An observational study in Childhood Liver Cancer, Liver Malignant Tumors and Embryonal Sarcoma of Liver (Disorder), sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 0 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by University of Pittsburgh · Observational

How we know

From the registry’s dates

  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
1,600
Ages
0 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
17th of 121
1,600 · median 132
Started
2015
with 35 others
Observational
121 of 926
26 open now
Primary completion
2030-06
later than 221 of 244 live
Registered
600th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 17th largest by planned enrollment of the 121 observational ones that give a count, is one of 36 that started in 2015, is one of 121 observational ones, reaches primary completion later than 221 of the 244 other live ones, and was the 600th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 0 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

Read the detailed description

Pediatric liver cancers are rare, affecting at times no more than 1 in one million population. Understanding the molecular basis of these cancers is important in order to develop more accurate diagnoses and more effective treatments. Current classifications of these cancers are based on how these cancers look on diagnostic studies such as radiologic imaging or under the microscope. Such a classification system does not explain why a particular cancer has a different outcome from what is considered "usual" for that particular cancer. Nor does such a classification system explain why two different classes of cancers behave the same way. Understanding the genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

To achieve these goals, large numbers of such cancer patients or affected tissue must be collected. This is not possible in any single institution, or any single country. The current project will collect biological samples such as residual tumor tissue, saliva, or blood from affected patients and their biological parents and families, along with clinical information about the cancer. These biological samples will be used to study the genes and how these genes work in tumor tissue and in non-tumor tissue. The results of this study will permit childhood liver cancers to be categorized on the basis of common defects in genes and their function.

03

Conditions studied

  • Childhood Liver Cancer
  • Liver Malignant Tumors
  • Embryonal Sarcoma of Liver (Disorder)
  • Hepatoblastoma
  • Hepatocellular Carcinoma
  • Rhabdoid Tumor of Liver

Keywords

  • Hepatoblastoma
  • Hepatocellular Carcinoma
  • Pediatric Liver Cancer
04

Who can participate

Ages eligible
0 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Living or deceased individuals who were diagnosed with a liver tumor, malignant or benign, during childhood (age \<21 years) and their biological parents and siblings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior or current treatment for a childhood liver tumor, malignant or benign, at age \<21 years.
  • Biological parents and siblings of eligible children.

Exclusion criteria

Exclusion Criteria:

  • No prior or current treatment for a childhood liver tumor.
  • Non-biological parents, legal guardians, or non-biological siblings of eligible children.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
1,600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Gene sequencing

    DNA sequence variants

    Time frame: Recurrence free survival at 2 years

  2. Gene expression analysis

    Differentially expressed genes

    Time frame: Recurrence free survival at 2 years

  3. Status of genome-wide chromatin accessibility

    chromatin accessibility

    Time frame: Duration of active chemotherapy to two years after surgical treatment

  4. Epigenetic change

    Differential methylation

    Time frame: Duration of active chemotherapy to two years after surgical treatment

  5. Tumor infiltrating cells which express immune checkpoints

    differentially enriched immune cells

    Time frame: Duration of active chemotherapy to two years after surgical treatment

Secondary outcomes

  1. Response to chemotherapy

    Survival

    Time frame: Duration of active chemotherapy to two years after surgical treatment

  2. Response to chemotherapy

    Relapse

    Time frame: Duration of active chemotherapy to two years after surgical treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Jun 2030, 180 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 180 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 22, 2019
StartActual
Jun 22, 2015
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2035
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03959800
Responsible party
Rakesh Sindhi (Professor of Surgery, University of Pittsburgh) — Principal investigator
First posted
May 22, 2019
Start date
Jun 22, 2015
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2035 (estimated)
Last update
Aug 10, 2026

Study contacts

Morgan Paul, BSN
Contact
Morgan.Paul2@upmc.edu
(412) 692-8472
Daniel Pieratt, MPA
Contact
pierattdw@upmc.edu
(412) 692-6692

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion